Comparisons › JNJ / PFE
Johnson & Johnson vs Pfizer: comparing JNJ and PFE stock
12-month growth, from 100━ JNJ +48.1% ━ PFE +27.7%
| Metric | JNJ | PFE |
|---|---|---|
| Price, $ | 272.32 | 29.88 |
| Year to date | +32.3% ● | +24.0% |
| 12 months | +48.1% ● | +27.7% |
| From 52-week high | −3.4% ● | −5.0% |
| vs 200-day average | +9.9% | +11.8% ● |
| P/E | 25.6 | 9.8 |
| Dividend yield | 1.96% | 5.64% ● |
| Revenue growth, YoY | +7.8% ● | +1.3% |
| Operating income growth | +7.7% | +8.5% ● |
| Operating margin | 26.6% | 29.0% ● |
| Gross margin | 67.8% | 74.9% ● |
| Market cap | $655.6B | $170.3B |
| Next earnings | Jan 26, 2027 | Feb 2, 2027 |
● — whose figure is higher, not which is better. Data as of Nov 5, 2026.
Ratings and a detailed chart for each are in the terminal.
Open the terminalFAQ
Which is better to buy: Johnson & Johnson or Pfizer?
We do not advise what to buy. By the numbers: Johnson & Johnson rose more over the year (+48.1%); Johnson & Johnson is closer to its 52-week high; Pfizer has the higher operating margin; Johnson & Johnson is growing revenue faster; Pfizer has the lower P/E. How to weigh such signs is covered in «How to analyse a stock».
Can I buy both?
Yes. Many hold several companies in one industry to avoid depending on one. A broad index fund often already holds the largest US companies.
When do they report?
Johnson & Johnson — Jan 26, 2027; Pfizer — Feb 2, 2027.